proxalutamide

02/22/2021 - "Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial."
02/22/2021 - "Conclusion Proxalutamide significantly accelerated viral clearance on Day 7 in mild to moderate COVID-19 patients versus placebo. Further, the time to clinical remission was significantly reduced in patients treated with Proxalutamide versus placebo."
12/01/2021 - "Results were similar between the two different arms, providing further consistency for the efficacy of proxalutamide when used in late-stage COVID-19."
01/01/2023 - "The findings of this study might lead to the development of better treatment for COVID-19 and provide convincing evidence regarding the efficacy and safety of proxalutamide. "
01/01/2023 - "Due to continued interest in proxalutamide, which is in phase 3 trials, we examined its ability to impact SARS-CoV-2 infection and downstream inflammatory responses. "

02/15/2021 - "Proxalutamide is a novel drug for the treatment of prostate cancer. "
01/01/2020 - "Furthermore, GT0918 significantly inhibited the growth of prostate cancer. "
11/20/2014 - "The aim of the present work was to design a pH-modified solid dispersion (pH(M)-SD) that can improve the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug. "
11/20/2014 - "Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo."
01/01/2023 - "Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter, randomized, open-label, phase 2 trial."

11/01/2022 - "This study aimed to evaluate the preliminary efficacy and safety of proxalutamide in patients with AR-positive metastatic breast cancer (AR+ mBC). "
10/01/2021 - "To evaluate GT0918, a 2nd-generation AR antagonist, for its AR down-regulation activity among breast cancer patients. "
10/01/2021 - "GT0918 can effectively inhibit AR-positive breast cancer tumor growth. "
11/01/2022 - "Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis."
10/01/2021 - "The effect of GT0918 on AR protein expression was evaluated in AR expression breast cancer cells and in breast cancer xenograft model. "

01/01/2023 - "The trial is the first to investigate the efficacy and safety of proxalutamide in severe or critically ill patients with COVID-19. "
01/01/2023 - "Thus, this trial is designed to investigate the efficacy and safety of proxalutamide in severe or critically ill patients with COVID-19. "
01/01/2023 - "Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial."

01/01/2023 - "Mechanistically, we found that proxalutamide increased levels of NRF2, an essential transcription factor that mediates antioxidant responses, and decreased lung inflammation. "